ATE450604T1 - Gsk3-polypeptide - Google Patents

Gsk3-polypeptide

Info

Publication number
ATE450604T1
ATE450604T1 AT07022387T AT07022387T ATE450604T1 AT E450604 T1 ATE450604 T1 AT E450604T1 AT 07022387 T AT07022387 T AT 07022387T AT 07022387 T AT07022387 T AT 07022387T AT E450604 T1 ATE450604 T1 AT E450604T1
Authority
AT
Austria
Prior art keywords
gsk3
polypeptides
amino acid
substituted amino
type
Prior art date
Application number
AT07022387T
Other languages
English (en)
Inventor
Stephen D Harrison
John A Hall
Maria Calderon-Cacia
Ziyang Zhong
Eric Y Fang
Doris G Coit
Steven H Nguyen
Angelica Medina-Selby
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE450604T1 publication Critical patent/ATE450604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
AT07022387T 2000-07-27 2001-07-25 Gsk3-polypeptide ATE450604T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22124200P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ATE450604T1 true ATE450604T1 (de) 2009-12-15

Family

ID=22826991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07022387T ATE450604T1 (de) 2000-07-27 2001-07-25 Gsk3-polypeptide

Country Status (10)

Country Link
US (6) US6465231B2 (de)
EP (2) EP1914305B1 (de)
JP (1) JP2004504838A (de)
CN (1) CN1276974C (de)
AT (1) ATE450604T1 (de)
AU (1) AU2001280812A1 (de)
DE (2) DE60131550T2 (de)
ES (1) ES2295191T3 (de)
PT (2) PT1914305E (de)
WO (1) WO2002010357A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360286A2 (de) * 2000-09-19 2003-11-12 Chiron Corporation Charakterisierung des gsk-3beta proteins und verfahren zu dessen verwendung
EP1504368A4 (de) * 2002-02-11 2008-01-23 Novartis Vaccines & Diagnostic Verfahren zur kristallisation von menschlichem gsk3 und neue kristallstruktur davon
WO2005083111A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 alpha (gsk3a)
WO2006063302A2 (en) * 2004-12-10 2006-06-15 Wyeth Variants of glycogen synthase kinase 3 and uses thereof
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
JPWO2006073202A1 (ja) * 2005-01-04 2008-08-07 国立大学法人金沢大学 ＧＳＫ３β阻害効果に基づくがんの抑制および抗がん剤の評価方法
JP5301987B2 (ja) * 2005-06-20 2013-09-25 デコード・ジェネティクス・イーエイチエフ ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体
CA2618613A1 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (de) 2010-07-26 2017-03-15 Biomatrica, INC. Zusammensetzungen zur stabilisierung von dna, rna und proteinen in blut- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2015002729A2 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
CN117384983B (zh) * 2023-12-07 2024-02-23 中国中医科学院中药研究所 一种GSK-3α抑制剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591872A (en) * 1993-08-09 1997-01-07 The University Of Iowa Research Foundation Autoinducer molecule
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5693496A (en) * 1994-06-20 1997-12-02 Merck & Co., Inc. DNA encoding the mouse and human PH30 beta chain protein
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
JP2002516102A (ja) * 1998-05-28 2002-06-04 ザイモジェネティクス，インコーポレイティド Ｋｕｎｉｔｚドメインポリペプチド並びにその製造のための材料及び方法
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6057218A (en) * 1999-05-07 2000-05-02 Vanguard International Semiconductor Corporation Method for simultaneously manufacturing poly gate and polycide gate

Also Published As

Publication number Publication date
US20050048511A1 (en) 2005-03-03
CN1276974C (zh) 2006-09-27
EP1914305A1 (de) 2008-04-23
EP1914305B1 (de) 2009-12-02
DE60131550T2 (de) 2008-10-23
AU2001280812A1 (en) 2002-02-13
US20020082408A1 (en) 2002-06-27
JP2004504838A (ja) 2004-02-19
US7195886B2 (en) 2007-03-27
WO2002010357A2 (en) 2002-02-07
US20030077798A1 (en) 2003-04-24
WO2002010357A3 (en) 2003-04-03
US20060088932A1 (en) 2006-04-27
US7807430B2 (en) 2010-10-05
US7135321B2 (en) 2006-11-14
DE60140707D1 (de) 2010-01-14
EP1319064B1 (de) 2007-11-21
CN1468302A (zh) 2004-01-14
EP1319064A2 (de) 2003-06-18
US7361484B2 (en) 2008-04-22
ES2295191T3 (es) 2008-04-16
US6716624B2 (en) 2004-04-06
US6465231B2 (en) 2002-10-15
US20070249004A1 (en) 2007-10-25
DE60131550D1 (en) 2008-01-03
PT1914305E (pt) 2010-01-29
US20080182313A1 (en) 2008-07-31
PT1319064E (pt) 2008-02-29

Similar Documents

Publication Publication Date Title
ATE450604T1 (de) Gsk3-polypeptide
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE419865T1 (de) Verwendung von protein-kinase-n-beta
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
DE69422726D1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
DE60014659D1 (de) Pharmazeutische- und kosmetischezusammensetzungen enthaldend serinproteasen aus kabeljau und deren pharmazeutische und kosmetische verwendung
ATE227343T1 (de) Protease und verwandte dns-verbindungen
BR9806752A (pt) Ftalazinonas.
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
EA200400699A1 (ru) 3,4-дизамещенные, 3,5-дизамещенные и 3,4,5-замещенные пиперидины и пиперазины
WO2000034511A3 (de) Peptid screening test zum nachweis von ass
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE323505T1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE221882T1 (de) Neue substituierte n-methyl-n-(4-(4-(1h- benzimidazol-2-yl-amino)-piperidin-1-yl)- 2(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
DE69809785D1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
EA200600918A1 (ru) Васе455, вариант альтернативного сплайсинга бета-секретазы человека
DE69731620D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1914305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee